Keywords: UCB, Xyrem, Fibromyalgia, EMA, CHMP, Europe, Non-approval

EMA advisory says no to UCB's Xyrem for fibromyalgia

Article | 18 March 2011

Print This

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) yesterday told Belgian drugmaker UCB ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in